Pacira Pharm Inc (PCRX) Stock Price, Quote & News

Latest News on PCRX

Apr 17, 2025, 5:00 PM EDT - 1 day ago

Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

Apr 17, 2025, 10:00 AM EDT - 1 day ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation

Apr 11, 2025, 8:00 AM EDT - 7 days ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 10, 2025, 10:00 AM EDT - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation

Apr 9, 2025, 10:03 AM EDT - 9 days ago

Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act

Apr 8, 2025, 10:45 AM EDT - 10 days ago

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

Apr 8, 2025, 10:00 AM EDT - 10 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation

Apr 7, 2025, 4:30 PM EDT - 11 days ago

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

Apr 6, 2025, 10:00 AM EDT - 12 days ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 3, 2025, 8:00 AM EDT - 15 days ago

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Apr 1, 2025, 8:00 AM EDT - 17 days ago

Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Mar 20, 2025, 10:00 AM EDT - 4 weeks ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 14, 2025, 5:27 PM EDT - 5 weeks ago

Pacira BioSciences: Back On An Uptrend After Positive Developments

Mar 14, 2025, 4:05 PM EDT - 5 weeks ago

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

Mar 14, 2025, 8:25 AM EDT - 5 weeks ago

DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences

Mar 13, 2025, 10:45 AM EDT - 5 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

Mar 3, 2025, 5:45 AM EST - 6 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX

Feb 27, 2025, 9:04 PM EST - 7 weeks ago

Pacira BioSciences, Inc. (PCRX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 7 weeks ago

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 27, 2025, 4:00 PM EST - 7 weeks ago

Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

Feb 26, 2025, 1:29 PM EST - 7 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit – PCRX

Feb 26, 2025, 8:00 AM EST - 7 weeks ago

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March

Feb 23, 2025, 10:23 AM EST - 7 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

Feb 20, 2025, 8:00 AM EST - 2 months ago

Pacira to Report 2024 Financial Results on Thursday February 27, 2025

Feb 20, 2025, 5:45 AM EST - 2 months ago

Market Cap	1.15B
Revenue (ttm)	700.97M
Net Income (ttm)	-99.56M
EPS (ttm)	N/A
PE Ratio	10.82
Forward PE	12.14
Profit Margin	-14.20%
Debt to Equity Ratio	0.39

Volume	450,000
Avg Vol	929,326
Day's Range	N/A - N/A
Shares Out	46.28M
Stochastic %K	46%
Beta	0.71
Analysts	Sell
Price Target	$34.28